| abstract |
A pyrazolopyridine compound according to formula (I) capable of inhibiting JAK, as well as pharmaceutically acceptable salts, solvates, solvates and biologically active metabolites of the pharmaceutically acceptable salts thereof are disclosed: Formula I Such compounds may be prepared as pharmaceutical compositions and may be associated with a variety of diseases in mammals, including humans, in particular, diseases that may be associated with abnormal JAK activity, including but not limited to allergy, inflammatory diseases, autoimmune diseases, proliferative diseases, It can be used for the treatment or prevention of graft rejection, diseases involving disorders of cartilage turnover, congenital cartilage malformations, and / or diseases associated with excessive secretion of IL6. |